Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07

Research in Microbiology

Volumn 158, Issue 4, 2007, Pages 355-362

  Vitali, Beatrice ^a   Turroni, Silvia ^a   Dal Piaz, Fabrizio ^a   Candela, Marco ^a   Wasinger, Valerie ^b   Brigidi, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Bifidobacteria; Probiotics; Proteomics; Rifaximin resistance; RNA polymerase; rpoB gene

Indexed keywords

ARGININE; BACTERIAL ENZYME; CHAPERONIN; GLUTAMINE; PROBIOTIC AGENT; RIFAXIMIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM MUTANT; BIFIDOBACTERIUM LONGUM INFANTIS; CODON; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SEQUENCE; GENETIC TRAIT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BIFIDOBACTERIUM; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MASS SPECTROMETRY; MUTATION; PROBIOTICS; PROTEOMICS; RIFAMYCINS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM LONGUM BV. INFANTIS;

EID: 34249318354     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2007.02.002     Document Type: Article

References (34)

1. Andreoni V., Bernasconi S., Colombo M., van Beilen J.B., and Cavalca L. Detection of genes for alkane and naphthalene catabolism in Rhodococcus sp. strain 1BN. Environ. Microbiol. 2 (2000) 572-577
2. Ankri S., Serebrijski I., Reyes O., and Leblon G. Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: a natural bypass of the proA step. J. Bacteriol. 178 (1996) 4412-4419
3. Bandow J.E., Brotz H., and Hecker M. Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J. Bacteriol. 184 (2002) 459-467
4. Brigidi P., Vitali B., Swennen E., Altomare L., Rossi M., and Matteuzzi D. Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst. Appl. Microbiol. 23 (2000) 391-399
5. Brigidi P., Swennen E., Rizzello F., Bozzolasco M., and Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J. Chemother. 14 (2002) 290-295
6. Caldas T., Laalami S., and Richarme G. Chaperone properties of bacterial elongation factor EF-G and initiation factor IF2. J. Biol. Chem. 275 (2000) 855-860
7. Fedorak R.N., and Madsen K.L. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10 (2004) 286-289
8. Ferianc P., Farewell A., and Nystrom T. The cadmium-stress stimulon of Escherichia coli K-12. Microbiology 144 (1998) 1045-1050
9. Gillis J.C., and Brogden R.N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49 (1995) 467-484
10. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers M.L., Brigidi P., Vitali B., Poggioli G., Miglioli M., and Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
11. Görg A., Postel W., and Günther S. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 9 (1988) 531-546
12. Guarner F., and Malagelada J.R. Gut flora in health and disease. Lancet 360 (2003) 512-519
13. Herrera L., Jimenez S., Valverde A., Garcia-Aranda M.A., and Saez-Nieto J.A. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int. J. Antimicrob. Agents 21 (2003) 403-408
14. Hui J., Gordon N., and Kajioka R. Permeability barrier to rifampicin in mycobacteria. Antimicrob. Agents Chemother. 11 (1977) 773-779
15. Humbert R., and Altendorf K. Defective gamma subunit of ATP synthase (F1F0) from Escherichia coli leads to resistance to aminoglycoside antibiotics. J. Bacteriol. 171 (1989) 1435-1444
16. Jin D.J., and Gross C.A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 202 (1988) 45-58
17. Marchese A., Salerno A., Pesce A., Debbia E.A., and Schito G.C. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46 (2000) 253-266
18. Marchi E., Montecchi L., Venturini A.P., Mascellari G., Brufani M., and Cellai L. 4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J. Med. Chem. 28 (1985) 960-963
19. McClure W.R., and Cech C.L. On the mechanism of rifampicin inhibition of RNA synthesis. J. Biol. Chem. 24 (1978) 8949-8956
20. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria. third ed. Approved Standard M11-A3 (1997), NCCLS, Wayne, PA
21. O'Toole R., and Williams H.D. Universal stress proteins and Mycobacterium tuberculosis. Res. Microbiol. 154 (2003) 387-392
22. Quan S., Venter H., and Dabbs E.R. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob. Agents Chemother. 41 (1997) 2456-2460
23. Quon D.V., d'Oliveira C.E., and Johnson P.J. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc. Natl. Acad. Sci. U.S.A. 15 (1992) 4402-4406
24. Sanchez B., Champomier-Vergès M.-C., Anglade P., Baraige F., de los Reyes-Gavilàn C.G., Margolles A., and Zagorec M. Proteomic analysis of global changes in protein expression during bile salt exposure of Bifidobacterium longum NCIMB 8809. J. Bacteriol. 16 (2005) 5799-5808
25. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
26. Schell M.A., Karmirantzou M., Snel B., Vilanova D., Berger B., Pessi G., Zwahlen M.C., Desiere F., Bork P., Delley M., Pridmore R.D., and Arigoni F. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14422-14427
27. Shaw K.J., Miller N., Liu X., Lerner D., Wan J., Bittner A., and Morrow B.J. Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents. J. Microbiol. Biotechnol. 5 (2003) 105-122
28. Shevchenko A., Wilm M., Vorm O., and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68 (1996) 850-858
29. Takahashi S., Kuzuyama T., Watanabe H., and Seto H. A 1-deoxy-d-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-d-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9879-9884
30. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., Matter L., Schopfer K., and Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341 (1993) 647-650
31. Thompson J.D., Higgens D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acid. Res. 22 (1994) 4673-4680
32. Yuen L.K.W., Leslie D., and Coloe P.J. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J. Clin. Microbiol. 37 (1999) 3844-3850
33. Vitali B., Wasinger V., Brigidi P., and Guilhaus M. A proteomic view of Bifidobacterium infantis generated by multi-dimensional chromatography coupled with tandem mass spectrometry. Proteomics 5 (2005) 1859-1867
34. Wasinger V.C., Pollack J.D., and Humphery-Smith I. The proteome of Mycoplasma genitalium. Chaps-soluble component. Eur. J. Biochem. 267 (2000) 1571-1582